YES, separating severe from critical for more detailed Interim analysis, could be the best decision of the year related to covid-19, leading to Leronlimab's approval. However, that would make the number of patients smaller each of these 2 Interim analyses, and thus, might not calculate out to improved p value? Am I missing something here?